KRAS and neoplasm: The patients with KRAS mutations (n = 13, 1.87 [1.31–2.56]) did not show statistically significant different TL in tumour tissue compared to the individuals with KRAS wild-type status (n = 19, 2.20 [1.58–2.98], T-test, p = 0.173).